Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Designing the Microbes and Social Equity Symposium: A Novel Interdisciplinary Virtual Research Conference Based on Achieving Group-Directed Outputs
Ishaq, Suzanne L. , Wissel, Emily , Grieneisen, Laura , Eggleston, Erin M. , Mhuireach, Gwynne , Friedman, Michael , Lichtenwalner, Anne , Machuca, Jessica Otero , Darling, Katherine Weatherford, Pearson, Amber L. , Wertheim, Frank S., Hodges, Leslie , Young, Sabrina K. , Nielsen, Charlene C. , MacRae, Jean D. , Myers, Elise M., Kozik, Ariangela J. , Tussing-Humphreys, Lisa Marie, Trujillo, Mónica , Daniel, Gaea , Donovan, Sharon M. , Arshad, Myra, Balkan, Joe, Hosler, Sarah, Wolf, Patricia G. , Johnson, Abigail J. , Kozyrskyj, Anita Luba , Tussing-Humphreys, Lisa Marie , Kramer, Michael R.

Mayo Clinic

Challenges | July 12, 2022 | Volume: 13 | Issue: 2 | Pages: 30

10.3390/challe13020030 Get It

The Microbes and Social Equity working group was formed in 2020 to foster conversations on research, education, and policy related to how microorganisms connect to personal, societal, and environmental health, and to provide space and guidance for action. In 2021, we designed our first virtual symposium to convene researchers already working in these areas for more guided discussions. The symposium organizing team had never planned a research event of this scale or style, and this perspective piece details that process and our reflections. The goals were to (1) convene interdisciplinary audiences around topics involving microbiomes and health, (2) stimulate conversation around a selected list of paramount research topics, and (3) leverage the disciplinary and professional diversity of the group to create meaningful agendas and actionable items for attendees to continue to engage with after the meeting. Sixteen co-written documents were created during the symposium which contained ideas and resources, or identified barriers and solutions to creating equity in ways which would promote beneficial microbial interactions. The most remarked-upon aspect was the working time in the breakout rooms built into the schedule. MSE members agreed that in future symposia, providing interactive workshops, training, or collaborative working time would provide useful content, a novel conference activity, and allow attendees to accomplish other work-oriented goals simultaneously.
Endothelin-1 as a novel target for the prevention of metabolic dysfunction with intermittent hypoxia in male participants
Limberg, Jacqueline K. , Baker, Sarah E. , Petersen‐Jones, Humphrey G., Guo, Winston , Huang, An , Jensen, Michael D. , Singh, Prachi , Baker, Sarah E , Singh, Prachi , Huang, An

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | July 11, 2022 | Volume: 323 | Issue: 3 | Pages: R351-R362

10.1152/ajpregu.00301.2021 | PMID 35816718 Get It

We examined the effect of intermittent hypoxia (IH, a hallmark feature of sleep apnea) on adipose tissue lipolysis and the role of endothelin-1 (ET-1) in this response. We hypothesized that IH can increase ET-1 secretion and plasma free fatty acid (FFA) concentrations. We further hypothesized that inhibition of ET-1 receptor activation with bosentan could prevent any IH-mediated increase in FFA. To test this hypothesis, 16 healthy male participants (32 ± 5 yr, 26 ± 2 kg/m2) were exposed to 30 min of IH in the absence (control) and presence of bosentan (62.5 mg oral twice daily for 3 days prior). Arterial blood samples for ET-1, epinephrine, and FFA concentrations, as well as abdominal subcutaneous adipose tissue biopsies (to assess transcription of cellular receptors/proteins involved in lipolysis), were collected. Additional proof-of-concept studies were conducted in vitro using primary differentiated human white preadipocytes (HWPs). We show that IH increased circulating ET-1, epinephrine, and FFA ( P < 0.05). Bosentan treatment reduced plasma epinephrine concentrations and blunted IH-mediated increases in FFA ( P < 0.01). In adipose tissue, bosentan had no effect on cellular receptors and proteins involved in lipolysis ( P > 0.05). ET-1 treatment did not directly induce lipolysis in differentiated HWP. In conclusion, IH increases plasma ET-1 and FFA concentrations. Inhibition of ET-1 receptors with bosentan attenuates the FFA increase in response to IH. Based on a lack of a direct effect of ET-1 in HWP, we speculate the effect of bosentan on circulating FFA in vivo may be secondary to its ability to reduce sympathoadrenal tone.
The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients
Liu, Julia J. , Abraham, Bincy , Adamson, Paula, Brister, Kelly A. , Damas, Oriana M. , Glover, Sarah C. , Hooks, Kimberly, Ingram, Ana, Loftus, Edward V. , McGovern, Dermot , Narain-Blackwell, Melodie, Odufalu, Florence-Damilola , Quezada, Sandra, Reeves, Vonda, Shen, Bo , Ward, Latonia, Loftus, Edward V , Liu, Julia J , Barnes, Edward L. , Kaplan, Gilaad G. , Stappenbeck, Thaddeus S. , McGovern, Dermot P.B.

Mayo Clinic

Inflammatory Bowel Diseases | July 11, 2022 | Volume: 29 | Issue: 2 | Pages: 297-307

10.1093/ibd/izac124 | PMID 35816130 Get It

Abstract Research on the care of inflammatory bowel disease (IBD) patients has been primarily in populations of European ancestry. However, the incidence of IBD, which comprises Crohn’s disease and ulcerative colitis, is increasing in different populations around the world. In this comprehensive review, we examine the epidemiology, clinical presentations, disease phenotypes, treatment outcomes, social determinants of health, and genetic and environmental factors in the pathogenesis of IBD in Black and Hispanic patients in the United States. To improve health equity of underserved minorities with IBD, we identified the following priority areas: access to care, accurate assessment of treatment outcomes, incorporation of Black and Hispanic patients in therapeutic clinical trials, and investigation of environmental factors that lead to the increase in disease incidence.
A Case of Adult Multisystem Inflammatory Syndrome Following COVID-19 Vaccine
Brown, Meghan, Garbajs, Nika Zorko , Mushtaq, Hisham, Jama, Abbas B, Rauf, Ibtisam , Mir, Mikael, Korsapati, Aishwarya Reddy, Jain, Shikha , Adhikari, Ramesh , Lal, Amos , Domecq, Juan Pablo , Goksoy, Sarah, Bartlett, Brian, Jain, Nitesh , Khan, Syed Anjum , Garbajs, Nika Z, Zec, Simon , Khedr, Anwar , Koritala, Thoyaja , Jain, Nitesh Kumar, Lal, Amos , Domecq Graces, Juan Pablo , Mir, Mikael, Gajic, Ognjen , Sharma, Amit

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | July 9, 2022 | Volume: 12 | Issue: 4 | Pages: 7-13

10.55729/2000-9666.1087 | PMID 36262897 Get It

Multisystem inflammatory syndrome is a life-threatening condition associated with elevated inflammatory markers and multiple organ injury. A diagnosis of exclusion, it has been reported after severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) in children and adults; recently it has been described in some post-COVID-19 vaccinated individuals. The prognosis with supportive care and immunomodulatory therapy is good, although some individuals may require treatment in the intensive care unit (ICU). Here we report a case of a 58-year-old man who developed multi-organ failure after receiving the second dose of the Moderna mRNA-1273 COVID-19 vaccine. He required critical organ support in the ICU. An extensive workup was done to rule out alternative infectious and inflammatory processes. Following a period of gradual in-hospital convalescence, our patient made a full recovery. To our knowledge, this is the first comprehensively described case of multisystem inflammatory syndrome associated with Moderna mRNA-1273 COVID-19 vaccine in an adult over 50 years of age.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with β-amyloid-PET, neurodegeneration and cognition
Chatterjee, Pratishtha , Vermunt, Lisa , Gordon, Brian A. , Pedrini, Steve , Boonkamp, Lynn, Armstrong, Nicola J. , Luo, Jingqin , Singh, Abhay Kumar , Li, Yan , Sohrabi, Hamid R. , Taddei, Kevin , Berman, Sarah , Chhatwal, Jasmeer P. , Graff-Radford, Neill, Day, Gregory S. , Farlow, Martin, Fox, Nick C. , Goate, Alison , Hassenstab, Jason , Xiong, Chengjie , Perrin, Richard J. , Fagan, Anne M. , Morris, John C. , Gordon, Brian A , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Luo, Jingqin , Berman, Sarah , Boonkamp, Lynn , Molloy, Mark P. , Benzinger, Tammie L.S. , Morris, John , Karch, Celeste M. , Cruchaga, Carlos , Farlow, Martin R. , Lee, Jae Hong , McDade, Eric , Mori, Hiroshi , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Jucker, Mathias , Masters, Colin L. , Bateman, Randall J. , Martins, Ralph N. , Teunissen, Charlotte E.

Mayo Clinic

No container title available | July 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1752559/v2 Get It

Abstract Glial fibrillary acidic protein (GFAP) is a promising candidate blood-based biomarker for Alzheimer’s disease (AD) diagnosis and prognostication. The timing of its disease-associated changes, its clinical correlates, and biofluid-type dependency will influence its clinical utility. We evaluated plasma, serum, and CSF GFAP in families with autosomal dominant AD (ADAD), leveraging the predictable age at symptom onset to determine changes by stage of disease. Plasma GFAP elevations appear a decade before expected symptom onset, after β-amyloid accumulation and prior to neurodegeneration and cognitive decline. Plasma GFAP distinguished β-amyloid-positive from β-amyloid-negative ADAD participants and showed a stronger relationship with β-amyloid load in asymptomatic than symptomatic ADAD. Higher plasma GFAP was associated with the degree and rate of neurodegeneration and cognitive impairment. Serum GFAP showed similar relationships, but these were less pronounced for CSF GFAP. Our findings support a role for plasma GFAP as a clinical biomarker for β-amyloid-associated cognitive deterioration in AD.
STOPS
Lund, Sarah , Woerster, Malin, Sawatsky, Adam P. , Dozois, Eric J. , D’Angelo, Anne-Lise D. , D'Angelo, Jonathan D, Kelley, Scott R. , D'Angelo, Anne-Lise D, D’Angelo, Jonathan D.

Mayo Clinic

Annals of Surgery | July 7, 2022 | Volume: 276 | Issue: 2 | Pages: 288-292

10.1097/sla.0000000000005447 | PMID 35797637 Get It

Objective: To investigate the steps faculty surgeons take upon experiencing intraoperative error and synthesize these actions to offer a framework for coping with errors. Background: While intraoperative errors are inevitable, formal training in error recovery is insufficient and there are no established curricula that teach surgeons how to deal with the intraoperative error. This is problematic because insufficient error recovery is detrimental to both patient outcomes and surgeon psychological well-being. Methods: We conducted a thematic analysis. One-hour in-depth semistructured interviews were conducted with faculty surgeons from 3 hospitals. Surgeons described recent experiences with intraoperative error. Interviews were transcribed and coded. Analysis allowed for development of themes regarding responses to errors and coping strategies. Results: Twenty-seven surgeons (30% female) participated. Upon completion of the analysis, themes emerged in 3 distinct areas: (1) Exigency, or a need for training surgical learners how to cope with intraoperative errors, (2) Learning, or how faculty surgeons themselves learned to cope with intraoperative errors, and (3) Responses, or how surgeons now handle intraoperative errors. The latter category was organized into the STOPS framework: Intraoperative errors could produce STOPS: Stop, Talk to your Team, Obtain Help, Plan, Succeed. Conclusions and Relevance: This study provides both novel insight into how surgeons cope with intraoperative errors and a framework that may be of great use to trainees and faculty alike.
Risk factors for breast cancer–related lymphedema in patients undergoing 3 years of prospective surveillance with intervention
Koelmeyer, Louise , Gaitatzis, Katrina , Dietrich, Mary S. , Shah, Chirag , Boyages, John , McLaughlin, Sarah A. , Taback, Bret , Stolldorf, Deonni P. , Hughes, Michael , French, James , Ngui, Nicholas , Hsu, Jeremy , Moore, Andrew , Ridner, Sheila H. , Koelmeyer, Louise A , Shah, Chirag S , Ridner, Sheila H , Elder, Elisabeth Edström , Moore, Andrew

Mayo Clinic

Cancer | July 7, 2022 | Volume: 128 | Issue: 18 | Pages: 3408-3415

10.1002/cncr.34377 | PMID 35797441 Get It

BackgroundTo evaluate risk factors (treatment‐related, comorbidities, and lifestyle) for breast cancer–related lymphedema (BCRL) within the context of a Prospective Surveillance and Early Intervention (PSEI) model of care for subclinical BCRL.MethodsThe parent randomized clinical trial assigned patients newly diagnosed with breast cancer to PSEI with either bioimpedance spectroscopy (BIS) or tape measurement (TM). Surgical, systemic and radiation treatments, comorbidities, and lifestyle factors were recorded. Detection of subclinical BCRL (change from baseline of either BIS L‐Dex ≥6.5 or tape volume ≥ 5% and < 10%) triggered an intervention with compression therapy. Volume change from baseline ≥10% indicated progression to chronic lymphedema and need for complex decongestive physiotherapy. In this secondary analysis, multinomial logistic regressions including main and interaction effects of the study group and risk factors were used to test for factor associations with outcomes (no lymphedema, subclinical lymphedema, progression to chronic lymphedema after intervention, progression to chronic lymphedema without intervention). Post hoc tests of significant interaction effects were conducted using Bonferroni‐corrected alphas of .008; otherwise, an alpha of .05 was used for statistical significance.ResultsThe sample (n = 918; TM = 457; BIS = 461) was female with a median age of 58.4 years. Factors associated with BCRL risk included axillary lymph node dissection (ALND) (p < .001), taxane‐based chemotherapy (p < .001), regional nodal irradiation (RNI) (p ≤ .001), body mass index >30 (p = .002), and rurality (p = .037). Mastectomy, age, hypertension, diabetes, seroma, smoking, and air travel were not associated with BCRL risk.ConclusionsWithin the context of 3 years of PSEI for subclinical lymphedema, variables of ALND, taxane‐based chemotherapy, RNI, body mass index >30, and rurality increased risk.
Multifidus Sarcopenia Is Associated With Worse Patient-reported Outcomes Following Posterior Cervical Decompression and Fusion
Townsley, Sarah, Omar, Adan, Freedman, Brett A. , Currier, Bradford L. , Elder, Benjamin D. , Bydon, Mohamad , Wagner, Scott C. , Sebastian, Arjun S. , Pinter, Zachariah W. , Salmons, Harold I. , Nassr, Ahmad

Mayo Clinic

Spine | July 7, 2022 | Volume: 47 | Issue: 20 | Pages: 1426-1434

10.1097/brs.0000000000004386 | PMID 35797647 Get It

Study Design. Retrospective cohort study. Objective. The present study is the first to assess the impact of paraspinal sarcopenia on patient-reported outcome measures (PROMs) following posterior cervical decompression and fusion (PCDF). Summary of Background Data. While the impact of sarcopenia on PROMs following lumbar spine surgery is well-established, the impact of sarcopenia on PROMs following PCDF has not been investigated. Materials and Methods. We performed a retrospective review of patients undergoing PCDF from C2 to T2 at a single institution between the years 2017 and 2020. Two independent reviewers who were blinded to the clinical outcome scores utilized axial cuts of T2-weighted magnetic resonance imaging sequences to assess fatty infiltration of the bilateral multifidus muscles at the C5–C6 level and classify patients according to the Fuchs Modification of the Goutalier grading system. PROMs were then compared between subgroups. Results. We identified 99 patients for inclusion in this study, including 28 patients with mild sarcopenia, 45 patients with moderate sarcopenia, and 26 patients with severe sarcopenia. There was no difference in any preoperative PROM between the subgroups. Mean postoperative Neck Disability Index scores were lower in the mild and moderate sarcopenia subgroups (12.8 and 13.4, respectively) than in the severe sarcopenia subgroup (21.0, P <0.001). A higher percentage of patients with severe multifidus sarcopenia reported postoperative worsening of their Neck Disability Index (10 patients, 38.5%; P =0.003), Visual Analog Scale Neck scores (7 patients, 26.9%; P =0.02), Patient-Reported Outcome Measurement Information System Physical Component Scores (10 patients, 38.5%; P =0.02), and Patient-Reported Outcome Measurement Information System Mental Component Scores (14 patients, 53.8%; P =0.02). Conclusion. Patients with more severe paraspinal sarcopenia demonstrate less improvement in neck disability and physical function postoperatively and are substantially more likely to report worsening PROMs postoperatively. Level of Evidence. 3.
SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
Dinnon, Kenneth H. , Leist, Sarah R. , Dang, Hong , Fritch, Ethan J. , Gully, Kendra L. , Cruz, Gabriela De la , Evangelista, Mia D. , Asakura, Takanori , Gilmore, Rodney C. , Hawkins, Padraig, Nakano, Satoko , West, Ande , Schäfer, Alexandra, Gralinski, Lisa E. , Zweigart, Mark R. , Dong, Stephanie , McBride, Jennifer , Cooley, Michelle R. , Hines, Jesse B., Love, Miriya K., Groshong, Steve D. , VanSchoiack, Alison , Phelan, Stefan, Liang, Yan , Hether, Tyler , Zumwalt, Ross E., Barton, Lisa M., Duval, Eric J., Stroberg, Edana , Borczuk, Alain , Thorne, Leigh B., Sakthivel, Muthu , Lee, Yueh Z. , Mock, Jason R. , Seibold, Max A. , O’Neal, Wanda K. , Montgomery, Stephanie A. , Boucher, Richard C. , Okuda, Kenichi , Dang, Hong , Fritch, Ethan J , Gully, Kendra L , De la Cruz, Gabriela , Evangelista, Mia D , Asakura, Takanori , Gilmore, Rodney C , Nakano, Satoko , West, Ande , Schäfer, Alexandra , Gralinski, Lisa E , Everman, Jamie L , Sajuthi, Satria P , Dong, Stephanie , McBride, Jennifer , Cooley, Michelle R , Groshong, Steve D , VanSchoiack, Alison , Phelan, Stefan J , Liang, Yan , Hether, Tyler , Leon, Michael , Sakthivel, Muthu K , Lee, Yueh Z , Hagood, James S , Mock, Jason R , Seibold, Max A , O'Neal, Wanda K , Montgomery, Stephanie A , Boucher, Richard C , Baric, Ralph S , Mukhopadhyay, Sanjay

Mayo Clinic

Science Translational Medicine | July 7, 2022 | Volume: 14 | Issue: 664 | Pages: No page available

10.1126/scitranslmed.abo5070 | PMID 35857635 Get It

A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal tissue samples. The mouse-adapted SARS-CoV-2 strain MA10 produces an acute respiratory distress syndrome in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute to clinical recovery phases. At 15 to 120 days after virus clearance, pulmonary histologic findings included subpleural lesions composed of collagen, proliferative fibroblasts, and chronic inflammation, including tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal up-regulation of profibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early antifibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC.
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials
Rutherford, Sarah C. , Yin, Jun , Pederson, Levi , Burbano, Gabriela Perez , LaPlant, Betsy, Kenkre, Vaishalee P. , Hong, Fangxin , Blum, Kristie A. , Dockter, Travis , Martin, Peter , Grant, Barbara, Rosenbaum, Cara A. , Ujjani, Chaitra S. , Cheson, Bruce D. , Bartlett, Nancy L. , Friedberg, Jonathan W. , Mandrekar, Sumithra J. , Leonard, John P. , Perez Burbano, Gabriela, Hong, Fangxin , Blum, Kristie A , Dockter, Travis , Martin, Peter , Jung, Sin‐Ho , Rosenbaum, Cara , Barr, Paul M , Unger, Joseph M , Cheson, Bruce D , Bartlett, Nancy L , Kahl, Brad S , Mandrekar, Sumithra J , Shadman, Mazyar , Li, Hongli , LeBlanc, Michael , Barr, Paul M. , Unger, Joseph M. , Kahl, Brad S.

Mayo Clinic

Journal of Clinical Oncology | July 5, 2022 | Volume: 41 | Issue: 2 | Pages: 336-342

10.1200/jco.21.02301 | PMID 35787017 Get It

PURPOSE Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in assessing response or predict progression-free survival (PFS) or overall survival (OS) outcomes in follicular lymphoma (FL) subjects in a large, multicenter, multitrial cohort. METHODS Data were pooled from seven trials of 580 subjects with previously untreated FL through Alliance for Clinical Trials in Oncology (Alliance) and SWOG Cancer Research Network (SWOG) completing enrollment from 2008 to 2016. RESULTS Only 5/580 (0.9%) had positive baseline BMB, CR on imaging, and subsequent positive BMB ( P < .0001). Therefore, BMB were irrelevant to response in 99% of subjects. A sensitivity analysis of 385 FL subjects treated on an Eastern Cooperative Oncology Group study was included. In the Eastern Cooperative Oncology Group cohort, 5/385 (1.3%) had BMB that affected response assessment. Since some subjects do not undergo confirmatory BMB, we performed a landmark survival analysis from first radiologic CR with data from 580 subjects from Alliance and SWOG. Of subjects with CR on imaging (n = 187), PFS and OS were not significantly different among those with negative BMB to confirm CR (n = 47) versus those without repeat BMB (n = 140; PFS: adjusted hazard ratio, 1.10, 95% CI, 0.62 to 1.94, log-rank P = .686; OS: hazard ratio, 0.59, 95% CI, 0.23 to 1.53, log-rank P = .276). CONCLUSION We conclude that BMB add little value to response assessment in subjects with FL treated on clinical trials and we recommend eliminating BMB from clinical trial requirements. BMB should also be removed from diagnostic guidelines for FL except in scenarios in which it may change management including confirmation of limited stage and assessment of cytopenias. This would reduce cost, patient discomfort, resource utilization, and potentially remove a barrier to trial enrollment.